Please login to the form below

Not currently logged in

Syros appoints Moderna CEO to board

Stéphane Bancel also has experience at bioMérieux and Lilly
Syros Stephane Bancel

The founding CEO of Moderna Therapeutics, Stéphane Bancel, has joined the board of Syros Pharmaceuticals.

Syros, which focuses on controlling a person's genes to treat cancer and other diseases, will benefit from Bancel's work in RNA therapeutics at Moderna.

The company's CEO Nancy Simonian said: “Stéphane has established an exceptional track record of accomplishment in our industry. His successes in financing and building companies as well as in creating value are widely admired.”

Bancel joined Moderna in 2011, the year after its formation. Notable achievements as CEO include securing a licensing partnership with AstraZeneca potentially worth more than $400m.

Prior to serving as Moderna's CEO, Bancel spent four years as CEO of bioMérieux.

He also spent six years at Lilly, including a spell as country manager for Belgium.

Commenting on his appointment to the board of Syros, he said: “Syros' leadership in understanding gene control opens entirely new avenues to treat cancer and other serious diseases.

“The company's revolutionary approach creates significant opportunity to impact health and create value.”

27th November 2013

From: Research, Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...